GST reforms, RDI scheme strengthened Indian pharma in 2025, innovation & access key for 2026 - The Hans India

New Delhi: With GST reforms and Research Development Incentive (RDI) Scheme, the year 2025 has been a crucial turning point for Indian pharma, said industry experts on Thursday, while highlighting innovation and increased access as key factors for the sector’s growth in 2026. Indian pharma is standing at a defining moment. In the past 25 years, the industry has grown from $3 billion to $60 billion…